Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain.
Department of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Galicia, Spain.
PLoS One. 2021 May 4;16(5):e0248886. doi: 10.1371/journal.pone.0248886. eCollection 2021.
B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregation of diverse tumors in pan-cancer genomic studies has become a useful tool to detect new driver genes, while enabling the comparison of mutational patterns across tumors. Here we present an integrated analysis of 354 B-cell lymphoid disorders. 112 recurrently mutated genes were discovered, of which KMT2D, CREBBP, IGLL5 and BCL2 were the most frequent, and 31 genes were putative new drivers. Mutations in CREBBP, TNFRSF14 and KMT2D predominated in follicular lymphoma, whereas those in BTG2, HTA-A and PIM1 were more frequent in diffuse large B-cell lymphoma. Additionally, we discovered 31 significantly mutated protein networks, reinforcing the role of genes such as CREBBP, EEF1A1, STAT6, GNA13 and TP53, but also pointing towards a myriad of infrequent players in lymphomagenesis. Finally, we report aberrant expression of oncogenes and tumor suppressors associated with novel noncoding mutations (DTX1 and S1PR2), and new recurrent copy number aberrations affecting immune check-point regulators (CD83, PVR) and B-cell specific genes (TNFRSF13C). Our analysis expands the number of mutational drivers of B-cell lymphoid neoplasms, and identifies several differential somatic events between disease subtypes.
B 细胞淋巴增生性疾病表现出多种诊断实体,具有异质的行为。多项努力集中在确定 B 细胞淋巴瘤亚型的基因组驱动因素上。与此同时,在泛癌基因组研究中聚集不同的肿瘤已成为检测新驱动基因的有用工具,同时能够比较肿瘤之间的突变模式。在这里,我们对 354 种 B 细胞淋巴样疾病进行了综合分析。发现了 112 个经常突变的基因,其中 KMT2D、CREBBP、IGLL5 和 BCL2 最为常见,有 31 个基因是潜在的新驱动基因。CREBBP、TNFRSF14 和 KMT2D 的突变在滤泡性淋巴瘤中占主导地位,而 BTG2、HTA-A 和 PIM1 的突变在弥漫性大 B 细胞淋巴瘤中更为常见。此外,我们还发现了 31 个显著突变的蛋白质网络,这加强了 CREBBP、EEF1A1、STAT6、GNA13 和 TP53 等基因的作用,但也指出了淋巴发生过程中有无数罕见的参与者。最后,我们报告了与新型非编码突变(DTX1 和 S1PR2)相关的癌基因和肿瘤抑制基因的异常表达,以及影响免疫检查点调节剂(CD83、PVR)和 B 细胞特异性基因(TNFRSF13C)的新的反复出现的拷贝数异常。我们的分析扩展了 B 细胞淋巴样肿瘤的突变驱动基因数量,并确定了疾病亚型之间的几个差异体细胞事件。